Solid Biosciences Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDSolid Biosciences Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings growth of 12% provides fundamental context to the price action. However, price is extended 25% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.52 | +23.53% | ABOVE |
| 50 SMA | $7.42 | +25.15% | ABOVE |
| 100 SMA | $7.18 | +29.31% | ABOVE |
| 150 SMA | $6.68 | +39.06% | ABOVE |
| 200 SMA | $6.37 | +45.93% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SLDB in an uptrend right now?
SLDB has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, SLDB is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is SLDB overbought or oversold?
SLDB's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is SLDB outperforming the market?
SLDB has a Relative Strength (RS) Rating of 89 out of 99. Yes, SLDB is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is SLDB in its 52-week range?
SLDB is trading at $9.29, which is 95% of its 52-week high ($9.78) and 92% above its 52-week low ($3.79).
How volatile is SLDB?
SLDB has a Beta of 2.10 and 52-week volatility of 80%. It's more volatile than the S&P 500 - expect bigger swings.